Synopsis of Social media discussions
The discussions convey overall support and curiosity about the research, with examples like mentions of the 27% increase in negative tests and phrases like 'bold discoveries' and 'significantly reduce' reflecting a tone of optimism and importance. The tone and word choices suggest a recognition of the study's relevance in advancing treatments for methamphetamine use disorder.
Agreement
Moderate agreementMost discussions endorse the positive results and potential of the combined treatment, with many highlighting the significant reduction in methamphetamine use shown in the trial.
Interest
Moderate level of interestThe posts demonstrate moderate interest, as they focus on sharing study outcomes and highlighting their importance, but lack detailed critical analysis or personal insights.
Engagement
Moderate level of engagementParticipants reference specific data points such as increases in negative test results and mention the significance of treatment duration, indicating a moderate level of in-depth engagement.
Impact
Moderate level of impactThe discussion emphasizes the potential impact of the treatment as a notable development in addiction medicine, suggesting it could influence future treatment protocols.
Social Mentions
YouTube
2 Videos
12 Posts
Blogs
3 Articles
News
26 Articles
Metrics
Video Views
138
Total Likes
15
Extended Reach
31,226
Social Features
43
Timeline: Posts about article
Top Social Media Posts
Addiction Journal
For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional reductions in MA use up to 12 weeks. Read the full study by Michael Li @uclaFM and colleagues here https://t.co/HfjGeR3MZa https://t.co/TklAsrINy6
view full post
P
ADAPT-2 trial: People with methamphetamine UD receiving treatment with naltrexone + bupropion XL showed a greater increase in their probability of testing negative for MA after 12-week vs. placebo (15.8%: P=0.006) https://t.co/KHANNOD36r
view full post
AliAdyb-Bear
Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial - Li - Addiction - Wiley Online Library https://t.co/xgwxqQGekU
view full post
InterCoast Colleges
**Bold Discoveries in Battling Meth Use Disorder:** The latest ADAPT-2 trial shows that NTX + BUPN treatments significantly reduce methamphetamine use over 12 weeks compared to placebo.
view full post
ISSUP
RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
view full post
Posts referencing the article
E-Cigarettes for Smoking Cessation: Key Findings and Insights
This video provides quick summaries of our last 10 articles, focusing on electronic nicotine-delivery systems (e-cigarettes) in smoking cessation. Results indicate mixed effectiveness with a higher continuous abstinence rate in the e-cigarette group compared to the control group.
November 18, 2024
126 views
Insights on Electronic Nicotine Delivery Systems for Cessation
This video provides a roundup of key scientific articles, including a study on electronic nicotine-delivery systems for smoking cessation. The trial compared e-cigarette users with a control group, revealing higher short-term abstinence rates in the former while highlighting mixed effectiveness.
November 18, 2024
12 views
-
RT @AlyAdybBear: Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial - Li - Ad…
view full postJuly 10, 2024
1
-
AliAdyb-Bear
@AlyAdybBear (Twitter)Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT‐2 trial - Li - Addiction - Wiley Online Library https://t.co/xgwxqQGekU
view full postJuly 9, 2024
1
1
-
UCLA CHIPTS
@CHIPTS (Twitter)A recent publication by CHIPTS very own CP Core Scientist Dr. Michael Li on the “Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial," was highlighted on @UCLAHealth news. Read here: https://t.co/37fQ98hPZD https://t.co/0T7qN2BTFW
view full postJuly 2, 2024
-
P
@psychopharmacol (Twitter)ADAPT-2 trial: People with methamphetamine UD receiving treatment with naltrexone + bupropion XL showed a greater increase in their probability of testing negative for MA after 12-week vs. placebo (15.8%: P=0.006) https://t.co/KHANNOD36r
view full postJune 21, 2024
3
-
TOXIDROGAS UN
@ToxidrogasUN (Twitter)RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
view full postJune 17, 2024
5
-
InterCoast Colleges
@CareersOnTarget (Twitter)**Bold Discoveries in Battling Meth Use Disorder:** The latest ADAPT-2 trial shows that NTX + BUPN treatments significantly reduce methamphetamine use over 12 weeks compared to placebo.
view full postJune 17, 2024
-
Maria.
@MariaToxCli (Twitter)RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
view full postJune 17, 2024
5
-
Your Ally Foundation, Inc
@ally_foundation (Twitter)RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
view full postJune 17, 2024
5
-
Anja Busse
@un_anja (Twitter)RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
view full postJune 17, 2024
5
-
ISSUP
@issupnet (Twitter)RT @AddictionJrnl: For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional…
view full postJune 17, 2024
5
-
Addiction Journal
@AddictionJrnl (Twitter)For people with methamphetamine (MA) use disorder, treatment with NTX-BUPN beyond 6 weeks is associated with additional reductions in MA use up to 12 weeks. Read the full study by Michael Li @uclaFM and colleagues here https://t.co/HfjGeR3MZa https://t.co/TklAsrINy6
view full postJune 17, 2024
11
5
-
PsychiatryAI.com
@PsychiatryAIcom (Twitter)New Post: Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial https://t.co/kT4oFspRf5
view full postJune 12, 2024
Abstract Synopsis
- The ADAPT2 trial studied the effects of combined naltrexone and bupropion (NTXBUPN) on reducing methamphetamine use over 12 weeks, showing that those on NTXBUPN had a significantly higher likelihood of testing negative for methamphetamine than those on placebo.
- Participants receiving NTXBUPN in stage 1 continued to improve in stage 2, with a 92% increase in the chance of testing negative for methamphetamine, adding to an overall 27% increase over 12 weeks, while the placebo group showed a smaller 11.4% increase.
- The results indicate that extended-release naltrexone plus bupropion could be an effective treatment to reduce methamphetamine use, as evidenced by significant differences in drug test outcomes between the treatment and placebo groups during the trial.
Anja Busse
@un_anja (Twitter)